Skip to main content
SpringerLink
Log in

Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis

  • Systematic Review
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Background

Akathisia is a common and distressing movement disorder that can be associated with the use of antipsychotics. It is characterized by a subjective (inner restlessness) and an objective (excessive movements) component. Akathisia can have a negative impact on clinical outcome and even lead to treatment discontinuation. Although medication-induced akathisia is more commonly associated with the use of first-generation antipsychotics (FGAs), it also occurs with second-generation antipsychotics (SGAs), including the newly approved antipsychotics (NAPs) asenapine, lurasidone, iloperidone, cariprazine, and brexpiprazole. Until now, no meta-analysis has been published on the risk of akathisia for all NAPs, as monotherapy or adjunctive treatment, in patients with a severe mental illness.

Objective

The primary objectives of this systematic review and meta-analysis were to (i) compare akathisia incidence rates of the NAPs, as monotherapy or adjunctive treatment, in adult patients with a severe mental illness (i.e., schizophrenia, bipolar disorder, or major depressive disorder), using data from published and unpublished randomized controlled trials; and (ii) examine the role of several study characteristics explaining differences in akathisia incidence rates between studies.

Methods

A systematic literature search, using the PubMed, EMBASE, and Cochrane Library databases (until October 2018), was conducted for English-language placebo- as well as active-controlled clinical trials, including subjective (percentage of patients reporting akathisia) and/or scale-defined medication-induced akathisia incidence rates with NAPs (as monotherapy or as adjunctive treatment) in adult patients with schizophrenia, bipolar disorder, or major depressive disorder. Additional unpublished clinical trials were identified through the ClinicalTrials.gov electronic database. Two meta-analyses (incidence rates and odds ratio [OR] [placebo vs. active] of medication-induced akathisia with NAPs) were performed to obtain an optimal estimation of akathisia risks of adult patients with a severe mental illness under these treatment conditions and to assess the role of study characteristics.

Results

Two hundred and thirteen reports were selected as potentially eligible for our meta-analysis. Of these, 48 met the inclusion criteria. Eight records, identified through the ClinicalTrials.gov database and cross-referencing, and which fulfilled the inclusion criteria, were added, resulting in a total of 56 records (iloperidone = 5, asenapine = 11, lurasidone = 15, brexpiprazole = 13, cariprazine = 12). The estimated weighted mean incidence rate of akathisia was 7.7% (95% confidence interval [CI] 6.5–9.1), with estimates being 3.9% (95% CI 2.4–6.3) for iloperidone, 6.8% (95% CI 5.1–9.0) for asenapine, 10.0% (95% CI 7.4–13.5) for brexpiprazole, 12.7% (95% CI 10.1–16.1) for lurasidone, and 17.2% (95% CI 13.4–22.1) for cariprazine. After Tukey-adjustment for multiple testing, the incidence rate of akathisia was significantly (p < 0.05) lower for iloperidone than for brexpiprazole, lurasidone, and cariprazine. In addition, the incidence rate of akathisia was significantly (p < 0.05) lower for asenapine than for lurasidone and cariprazine. Finally, the incidence rate of akathisia was significantly (p < 0.05) lower for brexpiprazole than for cariprazine. Type of medication (p < 0.0001), diagnosis (p = 0.02), and race (p = 0.0003) significantly explained part of the heterogeneity of the incidence estimates of akathisia between studies. The estimated weighted OR of akathisia under medication, compared with placebo, was 2.43 (95% CI 1.91–3.10). The OR was smallest for iloperidone (OR 1.20; 95% CI 0.42–3.45) and increased for brexpiprazole (OR 2.04; 95% CI 1.09–3.83), asenapine (OR 2.37; 95% CI 1.32–4.27), lurasidone (OR 3.74; 95% CI 2.32–6.02), and cariprazine (OR 4.35; 95% CI 2.80–6.75). Only type of medication (p = 0.03) explained systematic differences in the OR for akathisia between placebo versus active treatment across studies. After Tukey-adjustment for multiple testing, no significant differences between these ORs were found. The severity of akathisia with NAPs generally is mild to moderate, only leading to treatment discontinuation in a minority of cases (< 5%).

Conclusions

The use of a NAP raises the akathisia risk more than two-fold when compared with patients receiving placebo. Although distinctions between the different NAPs were not clear in placebo-controlled trials, the results of our meta-analyses and systematic review generally indicate that these differences more than likely reflect real differences, with iloperidone showing the most and cariprazine showing the least benign akathisia profile. Moreover, due to patient characteristics and methodological issues, incidence rates of akathisia with NAPs found in this meta-analysis may even be an underestimation of true incidence rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Pringsheim T, Gardner D, Addington D, Martino D, Morgante F, Ricciardi L, et al. The assessment and treatment of antipsychotic-induced akathisia. Can J Psychiatry. 2018. https://doi.org/10.1177/0706743718760288 (Epub 2018 Jan 1).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Salem H, Nagpal C, Pigott T, Teixeira AL. Revisiting antipsychotic-induced akathisia: current issues and prospective challenges. Curr Neuropharmacol. 2017;15(5):789–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Forcen FE, Matsoukas K, Alici Y. Antipsychotic-induced akathisia in delirium: a systematic review. Palliat Support Care. 2016;14(1):77–84.

    Article  PubMed  Google Scholar 

  4. Lohr JB, Eidt CA, Abdulrazzaq Alfaraj A, Soliman MA. The clinical challenges of akathisia. CNS Spectr. 2015;20(Suppl 1):1–14.

    Article  PubMed  Google Scholar 

  5. Barnes TR. The Barnes Akathisia Rating Scale–revisited. J Psychopharmacol. 2003;17(4):365–70.

    Article  PubMed  Google Scholar 

  6. Savitt D, Jankovic J. Tardive syndromes. J Neurol Sci. 2018;389:35–42.

    Article  PubMed  Google Scholar 

  7. Tachere RO, Modirrousta M. Beyond anxiety and agitation: a clinical approach to akathisia. Aust Fam Phys. 2017;46(5):296–8.

    Google Scholar 

  8. Caroff SN, Campbell EC. Drug-induced extrapyramidal syndromes: implications for contemporary practice. Psychiatr Clin N Am. 2016;39(3):391–411.

    Article  Google Scholar 

  9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013.

    Book  Google Scholar 

  10. Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127–48 (viii).

    Article  PubMed  PubMed Central  Google Scholar 

  11. Kane JM, Barnes TR, Correll CU, et al. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J Psychopharmacol. 2010;24(7):1019–29.

    Article  CAS  PubMed  Google Scholar 

  12. Sachdev PS. Neuroleptic-induced movement disorders: an overview. Psychiatr Clin N Am. 2005;28(1):255–74 (x).

    Article  Google Scholar 

  13. Juncal-Ruiz M, Ramirez-Bonilla M, Gomez-Arnau J, et al. Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. Psychopharmacology. 2017;234(17):2563–70.

    Article  CAS  PubMed  Google Scholar 

  14. Chouinard G, Margolese HC. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res. 2005;76(2–3):247–65.

    Article  PubMed  Google Scholar 

  15. Weiden PJ, Manning R, Wolfgang CD, et al. A randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE study. CNS Drugs. 2016;30(8):735–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gbinigie II, Lasserson D. Clarithromycin-induced akathisia: a class effect of macrolides. BMJ Case Rep. 2016. https://doi.org/10.1136/bcr-2016-217421.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Asser A, Taba P. Psychostimulants and movement disorders. Front Neurol. 2015;6:75.

    PubMed  Google Scholar 

  18. Riesselman A, El-Mallakh RS. Akathisia with azithromycin. Ann Pharmacother. 2015;49(5):609.

    Article  PubMed  Google Scholar 

  19. Dressler D. Tardive dystonic syndrome induced by the calcium-channel blocker amlodipine. J Neural Transm (Vienna). 2014;121(4):367–9.

    Article  CAS  PubMed  Google Scholar 

  20. Wright MT. Antiemetics, akathisia, and pregnancy. Psychosomatics. 2007;48(6):461–6.

    Article  PubMed  Google Scholar 

  21. Haddad PM, Das A, Keyhani S, Chaudhry IB. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. J Psychopharmacol. 2012;26(5 Suppl):15–26.

    Article  CAS  PubMed  Google Scholar 

  22. Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Berna F, Misdrahi D, Boyer L, Aouizerate B, Brunel L, Capdevielle D, FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group, et al. Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset. Schizophr Res. 2015;169(1–3):255–61.

    Article  CAS  PubMed  Google Scholar 

  24. Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16(6):1205–18.

    Article  CAS  PubMed  Google Scholar 

  25. Nasrallah HA, Earley W, Cutler AJ, Wang Y, Lu K, Laszlovszky I, et al. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry. 2017;17(1):305.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Martino D, Karnik V, Osland S, Barnes TRE, Pringsheim TM. Movement disorders associated with antipsychotic medication in people with schizophrenia: an overview of Cochrane reviews and meta-analysis. Can J Psychiatry. 2018;1:706743718777392.

    Google Scholar 

  27. Hirose S. The causes of underdiagnosing akathisia. Schizophr Bull. 2003;29(3):547–58.

    Article  PubMed  Google Scholar 

  28. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A 3rd, Assunção-Talbott S. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry. 2009;70(5):627–43.

    Article  CAS  PubMed  Google Scholar 

  29. Lipsey MW, Wilson DB. Practical meta-analysis. Thousand Oaks: Sage Publications; 2001.

    Google Scholar 

  30. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168(9):957–67.

    Article  PubMed  Google Scholar 

  31. Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47(5):670–7.

    Article  PubMed  Google Scholar 

  32. Ogasa M, Kimura T, Nakamura M, Guarino J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology. 2013;225(3):519–30.

    Article  CAS  PubMed  Google Scholar 

  33. Potkin SG, Kimura T, Guarino J. A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia. Ther Adv Psychopharmacol. 2015;5(6):322–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Landbloom RL, Mackle M, Wu X, et al. Asenapine: efficacy and safety of 5 and 10 mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder. J Affect Disord. 2016;190:103–10.

    Article  CAS  PubMed  Google Scholar 

  35. Kane JM, Lauriello J, Laska E, Di Marino M, Wolfgang CD. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S29–35.

    Article  CAS  PubMed  Google Scholar 

  36. Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S20–8.

    Article  CAS  PubMed  Google Scholar 

  37. Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S12–9.

    Article  CAS  PubMed  Google Scholar 

  38. Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S4–11.

    Article  CAS  PubMed  Google Scholar 

  39. Citrome L, Meng X, Hochfeld M, Stahl SM. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. Hum Psychopharmacol. 2012;27(1):24–32.

    Article  CAS  PubMed  Google Scholar 

  40. Potkin SG, Preskorn S, Hochfeld M, Meng X. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. J Clin Psychopharmacol. 2013;33(1):3–10.

    Article  CAS  PubMed  Google Scholar 

  41. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009;11(7):673–86.

    Article  CAS  PubMed  Google Scholar 

  42. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord. 2009;11(8):815–26.

    Article  CAS  PubMed  Google Scholar 

  43. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord. 2010;126(3):358–65.

    Article  CAS  PubMed  Google Scholar 

  44. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010;122(1–2):27–38.

    Article  CAS  PubMed  Google Scholar 

  45. Szegedi A, Calabrese JR, Stet L, Mackle M, Zhao J, Panagides J, Apollo Study Group. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. J Clin Psychopharmacol. 2012;32(1):46–55.

    Article  CAS  PubMed  Google Scholar 

  46. Azorin JM, Sapin C, Weiller E. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses. J Affect Disord. 2013;145(1):62–9.

    Article  CAS  PubMed  Google Scholar 

  47. Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010;30(2):106–15.

    Article  CAS  PubMed  Google Scholar 

  48. Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry. 2011;72(3):349–55.

    Article  PubMed  Google Scholar 

  49. Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R. Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010;43(4):138–46.

    Article  CAS  PubMed  Google Scholar 

  50. Schoemaker J, Stet L, Vrijland P, Naber D, Panagides J, Emsley R. Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study. Pharmacopsychiatry. 2012;45(5):196–203.

    CAS  PubMed  Google Scholar 

  51. Buchanan RW, Panagides J, Zhao J, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol. 2012;32(1):36–45.

    Article  CAS  PubMed  Google Scholar 

  52. Berk M, Tiller JW, Zhao J, Yatham LN, Malhi GS, Weiller E. Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis. J Clin Psychiatry. 2015;76(6):728–34.

    Article  PubMed  Google Scholar 

  53. Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology. 2016;233(14):2663–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Landbloom R, Mackle M, Wu X, Kelly L, Snow-Adami L, McIntyre RS, et al. Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr. 2017;22(4):333–41.

    Article  PubMed  Google Scholar 

  55. Durgam S, Landbloom RP, Mackle M, Wu X, Mathews M, Nasrallah HA. Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study. Neuropsychiatr Dis Treat. 2017;13:2021–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Szegedi A, Durgam S, Mackle M, Yu SY, Wu X, Mathews M, Landbloom RP. Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar i disorder. Am J Psychiatry. 2018;175(1):71–9.

    Article  PubMed  Google Scholar 

  57. Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103–13.

    Article  CAS  PubMed  Google Scholar 

  58. Durgam S, Earley W, Guo H, Li D, Németh G, Laszlovszky I, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016;77(3):371–8.

    Article  PubMed  Google Scholar 

  59. Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, Laszlovszky I. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015;17(1):63–75.

    Article  CAS  PubMed  Google Scholar 

  60. Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015;76(12):e1574–82.

    Article  PubMed  Google Scholar 

  61. Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152(2–3):450–7.

    Article  PubMed  Google Scholar 

  62. Calabrese JR, Keck PE Jr, Starace A, Lu K, Ruth A, Laszlovszky I, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015;76(3):284–92.

    Article  PubMed  Google Scholar 

  63. Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015;35(4):367–73.

    CAS  PubMed  Google Scholar 

  64. Sachs GS, Greenberg WM, Starace A, Lu K, Ruth A, Laszlovszky I, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disord. 2015;174:296–302.

    Article  CAS  PubMed  Google Scholar 

  65. Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, Németh G, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016;173(3):271–81.

    Article  PubMed  Google Scholar 

  66. Earley W, Durgam S, Lu K, Laszlovszky I, Debelle M, Kane JM. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2017;32(6):319–28.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Earley W, Durgam S, Lu K, Debelle M, Laszlovszky I, Vieta E, et al. Tolerability of cariprazine in the treatment of acute bipolar I mania: a pooled post hoc analysis of 3 phase II/III studies. J Affect Disord. 2017;215:205–12.

    Article  CAS  PubMed  Google Scholar 

  68. Lao KS, He Y, Wong IC, Besag FM, Chan EW. Tolerability and safety profile of cariprazine in treating psychotic disorders, bipolar disorder and major depressive disorder: a systematic review with meta-analysis of randomized controlled trials. CNS Drugs. 2016;30(11):1043–54.

    Article  CAS  PubMed  Google Scholar 

  69. Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Schizophr Res. 2016;176(2–3):264–71.

    Article  PubMed  Google Scholar 

  70. Durgam S, Litman RE, Papadakis K, Li D, Németh G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: a proof-of-concept trial. Int Clin Psychopharmacol. 2016;31(2):61–8.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Forest Laboratories. Safety and efficacy of RGH-188 (cariprazine) in bipolar depression. 2010 [ClinicalTrials.gov identifier NCT00852202]. National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 26 Sep 2018

  72. Ishigooka J, Iwashita S, Tadori Y. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: a 6-week, randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci. 2018;72(9):692–700.

    Article  CAS  PubMed  Google Scholar 

  73. Hobart M, Skuban A, Zhang P, Augustine C, Brewer C, Hefting N, et al. A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg/d as adjunctive treatment of adults with major depressive disorder. J Clin Psychiatry. 2018;79(4):17m12058. https://doi.org/10.4088/JCP.17m12058.

    Article  PubMed  Google Scholar 

  74. Hobart M, Skuban A, Zhang P, Josiassen MK, Hefting N, Augustine C, et al. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study. Curr Med Res Opin. 2018;34(4):633–42.

    Article  CAS  PubMed  Google Scholar 

  75. Fleischhacker WW, Hobart M, Ouyang J, Forbes A, Pfister S, McQuade RD, et al. Efficacy and safety of brexpiprazole (opc-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2017;20(1):11–21.

    CAS  PubMed  Google Scholar 

  76. Kane JM, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, et al. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr Res. 2016;174(1–3):93–8.

    Article  PubMed  Google Scholar 

  77. Correll CU, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, et al. Efficacy of brexpiprazole in patients with acute schizophrenia: review of three randomized, double-blind, placebo-controlled studies. Schizophr Res. 2016;174(1–3):82–92.

    Article  PubMed  Google Scholar 

  78. Citrome L, Ota A, Nagamizu K, Perry P, Weiller E, Baker RA. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. Int Clin Psychopharmacol. 2016;31(4):192–201.

    Article  PubMed  Google Scholar 

  79. Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76(9):1232–40.

    Article  PubMed  Google Scholar 

  80. Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76(9):1224–31.

    Article  PubMed  Google Scholar 

  81. McIntyre RS, Weiller E, Zhang P, Weiss C. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: results from a post hoc analysis of two randomised controlled trials. J Affect Disord. 2016;201:116–23.

    Article  CAS  PubMed  Google Scholar 

  82. Marder SR, Hakala MJ, Josiassen MK, Zhang P, Ouyang J, Weiller E, et al. Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies. Acta Neuropsychiatr. 2017;29(5):278–90.

    Article  PubMed  Google Scholar 

  83. Nelson JC, Weiller E, Zhang P, Weiss C, Hobart M. Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: a post hoc analysis of two pooled clinical studies. J Affect Disord. 2018;227:103–8.

    Article  CAS  PubMed  Google Scholar 

  84. Nelson JC, Zhang P, Skuban A, Hobart M, Weiss C, Weiller E, et al. Overview of short-term and long-term safety of brexpiprazole in patients with major depressive disorder and inadequate response to antidepressant treatment. Curr Psychiatry Rev. 2016;12:278–90.

    Article  CAS  Google Scholar 

  85. Yoon S, Jeon SW, Ko YH, Patkar AA, Masand PS, Pae CU, et al. Adjunctive brexpiprazole as a novel effective strategy for treating major depressive disorder: a systematic review and meta-analysis. J Clin Psychopharmacol. 2017;37(1):46–53.

    Article  CAS  PubMed  Google Scholar 

  86. Kane JM, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164(1–3):127–35.

    Article  PubMed  Google Scholar 

  87. Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(9):870–80.

    Article  PubMed  Google Scholar 

  88. H. Lundbeck A/S. Lighthouse trial. Interventional, randomised, double-blind, parallel-group, placebo-controlled, active-reference, flexible-dose study of brexpiprazole in patients with acute schizophrenia. 2014 [ClinicalTrials.gov identifier NCT01810380]. National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 26 Sep 2018

  89. Otsuka Pharmaceutical Development & Commercialization, Inc., Study of the safety and efficacy of OPC-34712 as adjunctive therapy in the treatment of patients with major depressive disorder [ClinicalTrials.gov identifier NCT00797966]. National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 26 Sep 2018

  90. Otsuka Pharmaceutical Development & Commercialization, Inc., Study of the safety and efficacy of OPC-34712 as adjunctive therapy in the treatment of adults with major depressive disorder (STEP-D222) [ClinicalTrials.gov identifier NCT01052077]. National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 26 Sep 2018

  91. Suppes T, Kroger H, Pikalov A, Loebel A. Lurasidone adjunctive with lithium or valproate for bipolar depression: a placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. J Psychiatr Res. 2016;78:86–93.

    Article  PubMed  Google Scholar 

  92. Suppes T, Silva R, Cucchiaro J, Mao Y, Targum S, Streicher C, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2016;173(4):400–7.

    Article  PubMed  Google Scholar 

  93. Loebel A, Silva R, Goldman R, Watabe K, Cucchiaro J, Citrome L, et al. Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study. J Clin Psychiatry. 2016;77(12):1672–80.

    Article  PubMed  Google Scholar 

  94. Loebel A, Citrome L, Correll CU, Xu J, Cucchiaro J, Kane JM. Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation. BMC Psychiatry. 2015;15:271.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160–8.

    Article  PubMed  Google Scholar 

  96. Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):169–77.

    Article  PubMed  Google Scholar 

  97. Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145(1–3):101–9.

    Article  PubMed  Google Scholar 

  98. Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane JM. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013;147(1):95–102.

    Article  PubMed  Google Scholar 

  99. Citrome L, Cucchiaro J, Sarma K, Phillips D, Silva R, Tsuchiya S, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012;27(3):165–76.

    Article  PubMed  Google Scholar 

  100. Potkin SG, Ogasa M, Cucchiaro J, Loebel A. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Res. 2011;132(2–3):101–7.

    Article  PubMed  Google Scholar 

  101. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829–36.

    Article  CAS  PubMed  Google Scholar 

  102. Sunovion, A randomized, double-blind, placebo-controlled, flexible-dose, parallel-group study of lurasidone adjunctive to lithium or divalproex for the prevention of recurrence in subjects with bipolar i disorder. 2015 [ClinicalTrials.gov identifier NCT01358357]. National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 26 Sep 2018

  103. Sunovion, A 6-week, double-blind, randomized, fixed-dose, parallel-group study of the efficacy and safety of three dose levels of sm-13496 compared to placebo and haloperidol in patients with schizophrenia who are experiencing an acute exacerbation of symptoms. 2003 [ClinicalTrials.gov identifier NCT00044044]. National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 26 Sep 2018

  104. Citrome L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol. 2017;37(2):138–47.

    Article  CAS  PubMed  Google Scholar 

  105. Thomas JE, Caballero J, Harrington CA. The incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: a meta-analysis. Curr Neuropharmacol. 2015;13(5):681–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Parikh NB, Robinson DM, Clayton AH. Clinical role of brexpiprazole in depression and schizophrenia. Ther Clin Risk Manag. 2017;13:299–306.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull. 2012;38(1):167–77.

    Article  PubMed  Google Scholar 

  108. Hope J, Castle D, Keks NA. Brexpiprazole: a new leaf on the partial dopamine agonist branch. Australas Psychiatry. 2018;26(1):92–4.

    Article  PubMed  Google Scholar 

  109. Cutler AJ, Durgam S, Wang Y, et al. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectr. 2018;23(1):39–50.

    Article  PubMed  Google Scholar 

  110. Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013;30(2):114–26.

    Article  CAS  PubMed  Google Scholar 

  111. Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013;9(2):193–206.

    Article  CAS  PubMed  Google Scholar 

  112. Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs. 2013;27(11):879–911.

    Article  CAS  PubMed  Google Scholar 

  113. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA. Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013;69(8):1497–509.

    Article  CAS  PubMed  Google Scholar 

  114. Durgam S, Greenberg WM, Li D, Lu K, Laszlovszky I, Nemeth G, et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology. 2017;234(2):199–209.

    Article  CAS  PubMed  Google Scholar 

  115. Scarff JR. Cariprazine for schizophrenia and bipolar disorder. Innov Clin Neurosci. 2016;13(9–10):49–52.

    PubMed  PubMed Central  Google Scholar 

  116. VRAYLAR® (cariprazine) capsules, for oral use. Highlights of prescribing information. Revised 11/2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204370s002s003lbl.pdf. Accessed 28 Sep 2018.

  117. Caccia S, Invernizzi RW, Nobili A, Pasina L. A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. Ther Clin Risk Manag. 2013;9:319–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Findlay LJ, El-Mallakh PL, El-Mallakh RS. Cariprazine for the treatment of bipolar disorder. Perspect Psychiatr Care. 2017;53(3):148–55.

    Article  PubMed  Google Scholar 

  119. Ketter TA, Sachs GS, Durgam S, Lu K, Starace A, Laszlovszky I, Németh G. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: a 16-week open-label study. J Affect Disord. 2018;225:350–6.

    Article  CAS  PubMed  Google Scholar 

  120. Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol. 2008;28(2):203–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. LATUDA® (Lurasidone HCl tablets). Highlights of prescribing information. Revised 3/2018. https://www.latuda.com/LatudaPrescribingInformation.pdf. Accessed 28 Sep 2018

  122. Jaeschke RR, Sowa-Kućma M, Pańczyszyn-Trzewik P, Misztak P, Styczeń K, Datka W. Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile. Pharmacol Rep. 2016;68(4):748–55.

    Article  CAS  PubMed  Google Scholar 

  123. Nasrallah HA, Cucchiaro JB, Mao Y, Pikalov AA, Loebel AD. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectr. 2015;20(2):140–7.

    Article  PubMed  Google Scholar 

  124. Zheng W, Cai DB, Yang XH, Li L, Zhang QE, Ng CH, et al. Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: a meta-analysis of randomized controlled trials. J Psychiatr Res. 2018;103:244–51.

    Article  PubMed  Google Scholar 

  125. Correll CU, Cucchiaro J, Silva R, Hsu J, Pikalov A, Loebel A. Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. CNS Spectr. 2016;21(5):393–402.

    Article  PubMed  Google Scholar 

  126. Stahl SM, Cucchiaro J, Simonelli D, Hsu J, Pikalov A, Loebel A. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry. 2013;74(5):507–15.

    Article  CAS  PubMed  Google Scholar 

  127. McEvoy JP, Citrome L, Hernandez D, Cucchiaro J, Hsu J, Pikalov A, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry. 2013;74(2):170–9.

    Article  CAS  PubMed  Google Scholar 

  128. Fornaro M, De Berardis D, Perna G, Solmi M, Veronese N, Orsolini L, et al. Lurasidone in the treatment of bipolar depression: systematic review of systematic reviews. Biomed Res Int. 2017;2017:3084859.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Findlay LJ, El-Mallakh P, El-Mallakh RS. Management of bipolar I depression: clinical utility of lurasidone. Ther Clin Risk Manag. 2015;11:75–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  130. Sanford M, Dhillon S. Lurasidone: a review of its use in adult patients with bipolar I depression. CNS Drugs. 2015;29(3):253–63.

    Article  CAS  PubMed  Google Scholar 

  131. Bawa R, Scarff JR. Lurasidone: a new treatment option for bipolar depression-a review. Innov Clin Neurosci. 2015;12(1–2):21–3.

    PubMed  PubMed Central  Google Scholar 

  132. Citrome L, Ketter TA, Cucchiaro J, Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2014;155:20–7.

    Article  CAS  PubMed  Google Scholar 

  133. McIntyre RS, Cha DS, Kim RD, Mansur RB. A review of FDA-approved treatment options in bipolar depression. CNS Spectr. 2013;18(Suppl 1):4–20.

    PubMed  Google Scholar 

  134. Woo YS, Wang HR, Bahk WM. Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatr Dis Treat. 2013;9:1521–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  135. Ketter TA, Miller S, Dell’Osso B, Calabrese JR, Frye MA, Citrome L. Balancing benefits and harms of treatments for acute bipolar depression. J Affect Disord. 2014;169(Suppl 1):S24–33.

    Article  CAS  PubMed  Google Scholar 

  136. McIntyre RS, Cucchiaro J, Pikalov A, Kroger H, Loebel A. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry. 2015;76(4):398–405.

    Article  PubMed  Google Scholar 

  137. Weiden PJ, Citrome L, Alva G, Brams M, Glick ID, Jackson R, et al. A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Schizophr Res. 2014;153(1–3):160–8.

    Article  PubMed  Google Scholar 

  138. Tonin FS, Wiens A, Fernandez-Llimos F, Pontarolo R. Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy. Core Evid. 2016;11:49–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Cutler AJ, Kalali AH, Mattingly GW, Kunovac J, Meng X. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. CNS Spectr. 2013;18(1):43–54.

    Article  PubMed  Google Scholar 

  140. Weiden PJ. Iloperidone for the treatment of schizophrenia: an updated clinical review. Clin Schizophr Relat Psychoses. 2012;6(1):34–44.

    Article  PubMed  Google Scholar 

  141. Citrome L. Iloperidone: a clinical overview. J Clin Psychiatry. 2011;72(Suppl 1):19–23.

    Article  CAS  PubMed  Google Scholar 

  142. FANAPT® (Iloperidone). Highlights of prescribing information. Revised 2/2017. https://www.fanapt.com/product/pi/pdf/fanapt.pdf. Accessed 28 Sep 2018.

  143. McIntyre RS. Asenapine: a review of acute and extension phase data in bipolar disorder. CNS Neurosci Ther. 2011;17(6):645–8.

    Article  CAS  PubMed  Google Scholar 

  144. Plosker GL, Deeks ED. Asenapine: a review in schizophrenia. CNS Drugs. 2016;30(7):655–66.

    Article  CAS  PubMed  Google Scholar 

  145. Scheidemantel T, Korobkova I, Rej S, Sajatovic M. Asenapine for bipolar disorder. Neuropsychiatr Dis Treat. 2015;11:3007–17.

    CAS  PubMed  PubMed Central  Google Scholar 

  146. McIntyre R, Landbloom R, Mackle M, Wu X, Kelly L, Snow-Adami L, et al. Efficacy and safety of asenapine 5 mg bid and 10 mg bid in adults with a manic or mixed episode associated with bipolar I disorder. Bipolar Disord. 2015;17(Suppl 1):92.

    Google Scholar 

  147. SAPHRIS (asenapine) sublingual tablets. Highlights of prescribing information. Revised 02/2017. https://www.allergan.com/assets/pdf/saphris_pi. Accessed 28 Sep 2018.

  148. Pompili M, Venturini P, Innamorati M, Serafini G, Telesforo L, Lester D, et al. The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder. Neuropsychiatr Dis Treat. 2011;7:259–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Cazorla P, Mackle M, Zhao J, Ha X, Szegedi A. Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia. Neuropsychiatr Dis Treat. 2012;8:247–57.

    CAS  PubMed  PubMed Central  Google Scholar 

  150. REXULTI® (Brexpiprazole tablets). Highlights of prescribing information. Revised 2/2018. https://www.otsuka-us.com/media/static/Rexulti-PI.pdf. Accessed 28 Sep 2018.

  151. Scarff JR. Brexpiprazole: a new treatment option for schizophrenia. Innov Clin Neurosci. 2016;13(7–8):26–9.

    PubMed  PubMed Central  Google Scholar 

  152. Correll CU, Skuban A, Ouyang J, Weiss C, Weiller E, Kane JM. Efficacy and safety of brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies. Eur Neuropsychopharmacol. 2015;25(Suppl 2):S522–3.

    Article  Google Scholar 

  153. Forbes A, Hobart M, Ouyang J, Shi L, Pfister S, Hakala M. A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as maintenance treatment in adults with schizophrenia. Int J Neuropsychopharmacol. 2018;21(5):433–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  154. Ishigooka J, Iwashita S, Tadori Y. Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: a 52-week, open-label study. Psychiatry Clin Neurosci. 2018;72(6):445–53.

    Article  CAS  PubMed  Google Scholar 

  155. Das S, Barnwal P, Winston AB, Mondal S, Saha I. Brexpiprazole: so far so good. Ther Adv Psychopharmacol. 2016;6(1):39–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  156. Markovic M, Gallipani A, Patel KH, Maroney M. Brexpiprazole. Ann Pharmacother. 2017;51(4):315–22.

    Article  CAS  PubMed  Google Scholar 

  157. Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med. 2010;122(4):39–48.

    Article  PubMed  Google Scholar 

  158. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008;28(1):13–20.

    Article  CAS  PubMed  Google Scholar 

  159. Takeuchi H, Thiyanavadivel S, Agid O, Remington G. Rapid vs. slow antipsychotic initiation in schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2018;193:29–36.

    Article  PubMed  Google Scholar 

  160. Stegmayer K, Walther S, van Harten P. Tardive dyskinesia associated with atypical antipsychotics: prevalence, mechanisms and management strategies. CNS Drugs. 2018;32(2):135–47.

    Article  CAS  PubMed  Google Scholar 

  161. Ormerod S, McDowell SE, Coleman JJ, Ferner RE. Ethnic differences in the risks of adverse reactions to drugs used in the treatment of psychoses and depression: a systematic review and meta-analysis. Drug Saf. 2008;31(7):597–607.

    Article  CAS  PubMed  Google Scholar 

  162. Zawar I, Caro MA, Feldman L, Jimenez XF. Acute movement disorders in the medical setting. Int J Psychiatry Med. 2016;51(5):395–413.

    Article  PubMed  Google Scholar 

  163. Hurd YL, Suzuki M, Sedvall GC. D1 and D2 dopamine receptor mRNA expression in whole hemisphere sections of the human brain. J Chem Neuroanat. 2001;22(1–2):127–37.

    Article  CAS  PubMed  Google Scholar 

  164. Patel J, Galdikas FJ, Marwaha R. Akathisia. [Updated 2019 Apr 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019. https://www.ncbi.nlm.nih.gov/books/NBK519543/.

  165. Stahl SM. Role of α1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms. CNS Spectr. 2013;18(6):285–8.

    Article  PubMed  Google Scholar 

  166. Stahl SM, Lonnen AJ. The mechanism of drug-induced akathisia. CNS Spectr. 2011;16(1):7–10.

    Article  Google Scholar 

  167. Corripio I, Ferreira A, Portella MJ, Pérez V, Escartí MJ, Del Valle Camacho M, et al. The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: iodine-123-iodobenzamide single photon emission computed tomography study. Psychiatry Res. 2012;201(1):73–7.

    Article  CAS  PubMed  Google Scholar 

  168. Lako IM, van den Heuvel ER, Knegtering H, Bruggeman R, Taxis K. Estimating dopamine D2 receptor occupancy for doses of 8 antipsychotics: a meta-analysis. J Clin Psychopharmacol. 2013;33(5):675–81.

    Article  CAS  PubMed  Google Scholar 

  169. Choi YK, Tarazi FI. Long-term effects of iloperidone on cerebral serotonin and adrenoceptor subtypes. J Mol Neurosci. 2018;66(1):59–67.

    Article  CAS  PubMed  Google Scholar 

  170. Kee Choi Y, Tarazi FI. Long-term effects of iloperidone on cerebral dopamine receptor subtypes. Synapse. 2018. https://doi.org/10.1002/syn.22039 (Epub 2018 Jun 23).

    Article  PubMed  Google Scholar 

  171. Saklad SR. Graphic representation of pharmacology: development of an alternative model. Ment Health Clin. 2018;7(5):201–6.

    Article  PubMed  PubMed Central  Google Scholar 

  172. Richelson E. New antipsychotic drugs: how do their receptor-binding profiles compare? J Clin Psychiatry. 2010;71(9):1243–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Koen Demyttenaere and Johan Detraux contributed equally to this work.

Authors and Affiliations

  1. Department of Neurosciences, Research Group Psychiatry, Department of Psychiatry, Faculty of Medicine, University Psychiatric Center KU Leuven and University of Leuven, Campus Gasthuisberg, Herestraat 49, 3000, Louvain, Belgium

    Koen Demyttenaere

  2. Department of Neurosciences, Research Group Psychiatry, KU Leuven, University Psychiatric Centre, 3070, Kortenberg, Belgium

    Johan Detraux & Kristof Vansteelandt

  3. Department of Pharmacological Sciences, Università degli Studi di Milano, Milan, Italy

    Giorgio Racagni

Authors
  1. Koen Demyttenaere
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johan Detraux
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giorgio Racagni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kristof Vansteelandt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koen Demyttenaere.

Ethics declarations

Conflict of interest

Koen Demyttenaere declares that he has received fees from Lundbeck, Servier, Boehringer Ingelheim, LivaNova, Pfizer, Recordati, and Johnson & Johnson in the past 3 years. Giorgio Racagni declares that he has received personal fees from Servier and Recordati. Johan Detraux and Kristof Vansteelandt have no conflict of interest to declare.

Funding

No funding was received in relation to this systematic review.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 40 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Demyttenaere, K., Detraux, J., Racagni, G. et al. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis. CNS Drugs 33, 549–566 (2019). https://doi.org/10.1007/s40263-019-00625-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-019-00625-3

Search

Navigation